E Fund Management Co. Ltd. Invests $4.86 Million in Erasca, Inc. $ERAS
E Fund Management Co. Ltd. has acquired a new stake worth $4.86 million in Erasca, Inc., purchasing 265,381 shares. Institutional investors now collectively own 67.78% of Erasca. The company holds a "Moderate Buy" consensus rating from analysts, despite reporting a quarterly loss of $0.14 per share, missing estimates.
Law firm probes Erasca directors for possible breaches of fiduciary duty to shareholders.
Bernstein Liebhard LLP is investigating Erasca, Inc. directors and officers for potential breaches of fiduciary duty to shareholders. The probe aims to determine if their actions align with shareholders' best interests and if legal recourse is necessary. Shareholders who purchased Erasca shares before January 14, 2025, are encouraged to contact the firm for a confidential consultation.
ERASCA, INC. (ERAS) SHAREHOLDER INVESTIGATION ALERT: Bernstein Liebhard Investigates Potential Breaches of Fiduciary Duty
Bernstein Liebhard LLP has launched an investigation into potential breaches of fiduciary duty by certain directors and officers of Erasca, Inc. (NASDAQ: ERAS). The investigation aims to determine if the company's leadership fulfilled its obligations to shareholders and whether legal remedies are appropriate. Shareholders who purchased Erasca shares before January 14, 2025, are encouraged to contact the firm for a confidential consultation.
81,900 Shares in Erasca, Inc. $ERAS Acquired by Handelsbanken Fonder AB
Handelsbanken Fonder AB recently acquired 81,900 shares of Erasca, Inc. (NASDAQ:ERAS) valued at approximately $1.5 million during the second quarter. Other institutional investors have also adjusted their holdings in Erasca, which currently has 67.78% institutional ownership. Despite missing EPS estimates in its latest quarterly report, the company maintains a "Moderate Buy" consensus rating among analysts with an average price target of $22.09.
Erasca, Inc. (ERAS) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims against Erasca, Inc. (ERAS) after the company disclosed receiving a letter from Revolution Medicines alleging patent infringement and trade secret misappropriation related to Erasca's ERAS-0015. Following this news, Erasca's stock price dropped significantly. The law firm is encouraging affected investors to contact them to learn more about the investigation.
Does Legal Scrutiny And Leadership Change Reshape The Bull Case For Erasca’s ERAS-0015 Program (ERAS)?
Erasca, Inc. recently reported wider net losses, filed a significant ESOP-related shelf registration, and is facing a securities class action lawsuit concerning its ERAS-0015 program. Despite these challenges, the company appointed a veteran oncologist-executive to lead R&D, aiming to strengthen its scientific oversight. The article examines how these developments, particularly the legal dispute, affect Erasca's investment narrative and highlight the varying analyst expectations for its stock.
Stifel reiterates Buy rating on Erasca stock, $30 target
Stifel has reiterated a Buy rating and a $30.00 price target on Erasca Inc. (NASDAQ: ERAS), despite the stock's significant surge over the past year and indications of potential overvaluation according to InvestingPro data. The company plans to advance its pan-RAS inhibitor ERAS-0015 into three registration-enabling studies starting in 2027, targeting non-small cell lung cancer and pancreatic ductal adenocarcinoma. This decision follows positive clinical trial updates and a successful public offering that raised approximately $632.5 million, contributing to increased analyst confidence and revised price targets from other firms.
Stifel reiterates Buy rating on Erasca stock, $30 target
Stifel reiterated a Buy rating and $30 price target for Erasca (NASDAQ:ERAS) due to the company's planned registration-enabling studies for its pan-RAS inhibitor ERAS-0015 in 2027. Erasca also recently reported promising second-quarter 2026 results, including a 57% unconfirmed overall response rate in pancreatic cancer patients and a successful public offering raising $632.5 million. Other analysts like Guggenheim, H.C. Wainwright, and Jefferies have also raised their price targets for Erasca, reflecting growing confidence in its oncology pipeline.
Does Legal Scrutiny And Leadership Change Reshape The Bull Case For Erasca’s ERAS-0015 Program (ERAS)?
Erasca, Inc. recently reported wider net losses, filed a significant ESOP-related shelf registration, and is facing a securities class action lawsuit concerning its ERAS-0015 program, though it has also appointed a new president of R&D. These developments introduce both scientific leadership strength and increased legal/financial uncertainty, impacting the investment narrative for ERAS-0015. The article highlights the divergence in fair value estimates for Erasca's stock, reflecting differing views on how these challenges will affect the company's future.
Erasca (ERAS) insiders report 10.4% and 5.6% ownership stakes
Erasca, Inc. has filed an amended passive investment disclosure (SCHEDULE 13G/A) detailing updated insider ownership. Jonathan E. Lim beneficially owns 10.4% of the common stock, while Conyee T. Lim holds a 5.6% beneficial stake. These figures are based on 349,762,035 shares outstanding as of August 4, 2026.
Erasca, Inc. (NASDAQ:ERAS) Receives Average Rating of "Moderate Buy" from Brokerages
Erasca, Inc. (NASDAQ:ERAS) has received a "Moderate Buy" consensus rating from eleven brokerages, with an average 12-month price target of $21.91. Despite a recent 3.9% decline in shares and missing analyst expectations for its quarterly loss, institutional investors hold a significant 67.78% of the stock. Several research firms have recently updated their price targets and ratings for Erasca.
Guggenheim raises Erasca stock price target to $21 on pipeline progress
Guggenheim has increased its price target for Erasca Inc. (NASDAQ: ERAS) to $21 from $20, maintaining a Buy rating, citing confidence in the company's RAS inhibitor pipeline progress. This follows Erasca's second-quarter 2026 results and a pipeline update, including advanced development plans for ERAS-0015 in non-small cell lung cancer and pancreatic ductal adenocarcinoma, and a collaboration with Merck. Other analysts like H.C. Wainwright and Jefferies have also raised their price targets for Erasca, highlighting strong trial data and the potential of its drug candidates.
Guggenheim raises Erasca stock price target to $21 on pipeline progress
Guggenheim raised its price target for Erasca Inc (NASDAQ:ERAS) to $21 from $20, maintaining a Buy rating, citing progress in the company's RAS inhibitor pipeline, particularly the ERAS-0015 program. This follows Erasca's second-quarter results, a $500 million equity raise, and a new clinical collaboration with Merck. Other analysts like H.C. Wainwright and Jefferies have also increased their price targets due to promising trial data and the drug's potential.
ERAS: ERAS-0015 delivers strong efficacy and safety in RAS-mutant cancers, advancing toward pivotal trials
ERAS-0015 is showing strong efficacy and safety in treating RAS-mutant cancers, including NSCLC and PDAC, with high response rates. The company has a robust pipeline targeting RAS/MAPK-driven cancers and strong financial backing to support upcoming pivotal trials. This positions ERAS as a potential leader in the competitive RAS-targeting oncology market.
ERAS Investors Have Opportunity to Lead Erasca, Inc. Securities Fraud Lawsuit with SBS Law
Schall, Brown & Schwartz LLP (SBS) has announced a class action lawsuit against Erasca, Inc. (NASDAQ: ERAS) for alleged securities fraud, stemming from misleading statements regarding its Preclinical data on ERAS-0015. Investors who purchased shares between January 14, 2025, and April 26, 2026, are encouraged to contact SBS to discuss their rights and the opportunity to become a lead plaintiff, with a deadline of August 10, 2026. The lawsuit claims that Erasca's public statements were false and materially misleading, causing investor damages when the truth emerged.
Erasca appoints Charles Fuchs as R&D president
Erasca Inc. (NASDAQ:ERAS) has appointed Charles S. Fuchs, M.D., M.P.H., as its new president of research and development. Dr. Fuchs brings over 30 years of oncology experience, including leadership roles at Genentech and Roche, where he oversaw the development of several approved therapies. Erasca is a clinical-stage precision oncology company focused on developing therapies for RAS/MAPK pathway-driven cancers.
CLASS ACTION DEADLINE TONIGHT: Faruqi & Faruqi, LLP Reminds Erasca (ERAS) Investors of Securities Class Action Lawsuit Deadline on August 10, 2026
Faruqi & Faruqi, LLP is reminding Erasca (NASDAQ: ERAS) investors of the August 10, 2026 deadline to seek lead plaintiff status in a federal securities class action lawsuit. The lawsuit alleges that Erasca made misleading statements regarding its ERAS-0015 drug candidate's preclinical data, which was based on improper comparisons and led to patent infringement claims and a patient death during clinical trials. Investors who purchased Erasca securities between January 14, 2025, and April 26, 2026, and suffered losses, may be eligible to participate.
CLASS ACTION DEADLINE TONIGHT: Faruqi & Faruqi, LLP Reminds Erasca (ERAS) Investors of Securities Class Action Lawsuit Deadline on August 10, 2026
Faruqi & Faruqi, LLP is reminding investors of the August 10, 2026 deadline to seek lead plaintiff status in a federal securities class action lawsuit against Erasca, Inc. (ERAS). The lawsuit alleges that Erasca and its executives violated federal securities laws by making false or misleading statements regarding the ERAS-007 drug candidate, particularly concerning its preclinical data comparisons and potential patent infringement risks. Investors who purchased ERAS securities between January 13, 2023, and April 26, 2026, and suffered losses are encouraged to contact the firm.
Erasca Strengthens R&D Leadership with Appointment of Internationally Recognized Medical Oncologist Charles S. Fuchs, M.D., M.P.H., as President of R&D
Erasca, Inc., a clinical-stage precision oncology company, has appointed Charles S. Fuchs, M.D., M.P.H., as its new President of Research and Development. Dr. Fuchs brings over thirty years of leadership experience in oncology, including significant roles in drug development at Genentech/Roche and as director of the Yale Cancer Center. His appointment aims to strengthen Erasca's R&D strategy, particularly in advancing its RAS-targeting franchise for treating RAS/MAPK pathway-driven cancers.
Charles Fuchs Brings More Than 3 Decades in Oncology to Erasca
Erasca (Nasdaq: ERAS), a clinical-stage precision oncology company, has appointed Charles S. Fuchs, M.D., M.P.H., as president of research and development. Dr. Fuchs brings over three decades of oncology leadership and expertise in drug development, scientific innovation, and patient care, with a focus on gastrointestinal cancers. His experience is expected to shape Erasca's R&D strategy as the company expands development and prepares for the potential commercialization of its RAS-targeting franchise, aiming to address unmet needs in RAS/MAPK pathway-driven cancers.
Kaplan Fox Alerts Erasca, Inc. (NASDAQ: ERAS) Investors to Seek Leadership in a Securities Fraud Lawsuit by August 10, 2026
Kaplan Fox & Kilsheimer LLP has filed a class action lawsuit against Erasca, Inc. (NASDAQ: ERAS) on behalf of investors who purchased securities between January 14, 2025, and April 26, 2026. The lawsuit alleges that Erasca made misleading statements regarding its drug ERAS-0015, which was accused by Revolution Medicines, Inc. of patent infringement and trade secret misappropriation. Investors who suffered losses and wish to serve as lead plaintiff must do so by August 10, 2026.
Erasca, Inc. Notice of August 10, 2026 Application Deadline for Class Action Lawsuit - Contact Reed Kathrein at Hagens Berman Sobol Shapiro LLP By Application Deadline
Hagens Berman is investigating a class action lawsuit against Erasca, Inc. (NASDAQ: ERAS) for alleged securities law violations. The lawsuit claims Erasca misled investors about its oncology candidate, ERAS-0015, regarding its competitive advantage, safety, and intellectual property, leading to a significant stock decline after disclosures of patent infringement allegations and a patient death. Investors who suffered losses and purchased stock between January 14, 2025, and April 26, 2026, have until August 10, 2026, to apply for lead plaintiff.
California State Teachers Retirement System Grows Position in Erasca, Inc. $ERAS
The California State Teachers Retirement System significantly increased its stake in Erasca, Inc. (NASDAQ:ERAS) by 1,812.7% in the first quarter of 2026, bringing its total holdings to 204,449 shares valued at $3.3 million. Despite facing investor lawsuits alleging misleading disclosures about its lead cancer drug candidate, ERAS-0015, the company maintains a "Moderate Buy" consensus rating from
Erasca, Inc. Notice of August 10, 2026 Application Deadline for Class Action Lawsuit - Contact Reed Kathrein at Hagens Berman Sobol Shapiro LLP Before Application Deadline
Hagens Berman is investigating Erasca, Inc. (NASDAQ: ERAS) for alleged securities law violations, claiming the company and its executives misled investors about its lead oncology candidate, ERAS-0015. The class action alleges false narratives regarding competitive advantage, safety, and intellectual property, with a lead plaintiff deadline of August 10, 2026. Investors who suffered significant losses during the period of January 14, 2025 – April 26, 2026, are urged to contact the firm.
ERASCA DEADLINE: ROSEN, SKILLED INVESTOR COUNSEL,
Rosen Law Firm is encouraging investors who purchased Erasca, Inc. (NASDAQ: ERAS) common stock between January 14, 2025, and April 26, 2026, to secure legal counsel before the August 10, 2026, lead plaintiff deadline for a securities class action lawsuit. The lawsuit alleges that Erasca, its CEO, and CFO made false and misleading statements about its oncology drug candidate, ERAS-0015, by improperly comparing it to a competitor's drug and failing to disclose related patent and trade secret risks. Investors are advised to contact Rosen Law Firm for information on joining the class action.
Erasca, Inc. Notice of August 10, 2026 Application Deadline for Class Action Lawsuit - Contact Lewis Kahn, Esq. at Kahn Swick & Foti, LLC, Before Application Deadline
Kahn Swick & Foti, LLC (KSF) has announced a class action securities lawsuit against Erasca, Inc. (NASDAQ: ERAS). Investors who purchased Erasca shares between January 14, 2025, and April 26, 2026, and suffered losses, are encouraged to contact KSF, with an application deadline for lead plaintiff set for August 10, 2026. The lawsuit alleges that Erasca and its executives failed to disclose material information regarding the preclinical data for their ERAS-0015 product, violating federal securities laws.
The Manufacturers Life Insurance Company Acquires 161,845 Shares of Erasca, Inc. $ERAS
The Manufacturers Life Insurance Company significantly increased its stake in Erasca, Inc. (NASDAQ:ERAS) by 295.5% in the first quarter, acquiring an additional 161,845 shares to own a total of 216,614 shares valued at approximately $3.5 million. This comes as Erasca faces investor lawsuits alleging misleading statements about its ERAS-0015 cancer candidate, with a deadline for lead-plaintiff status set for August 10, 2026. Despite missing earnings expectations, analysts maintain a "Moderate Buy" consensus for ERAS with an average price target of $21.64.
Bronstein, Gewirtz & Grossman LLC Urges Erasca, Inc. Investors to Act: Class Action Filed Alleging Investor Harm
Bronstein, Gewirtz & Grossman LLC has announced a class action lawsuit against Erasca, Inc. (NASDAQ: ERAS) and its officers, alleging violations of federal securities laws. The lawsuit claims that Erasca made misleading statements regarding ERAS-0015's preclinical data, which was based on improper comparisons and risked violating patent protections. Investors who purchased Erasca securities between January 14, 2025, and April 26, 2026, are encouraged to join the case, with a lead plaintiff deadline of August 10, 2026.
Erasca 72 Hour Deadline Alert: Kahn Swick & Foti, LLC Reminds Investors With Losses In Excess Of $100,000 of Deadline in Class Action Lawsuit Against Erasca, Inc. - ERAS
Kahn Swick & Foti, LLC (KSF) is reminding investors with losses exceeding $100,000 in Erasca, Inc. (ERAS) to file lead plaintiff applications by August 10, 2026, in a securities class action lawsuit. The lawsuit alleges that Erasca and its executives made false and misleading statements regarding the preclinical data for their ERAS-0015 product, potentially violating patent and trade secret protections. Investors who purchased Erasca shares between January 14, 2025, and April 26, 2026, are affected.
Erasca, Inc. Notice of August 10, 2026 Application Deadline for Class Action Lawsuit - Contact Lewis Kahn, Esq. at Kahn Swick & Foti, LLC, Before Application Deadline
Kahn Swick & Foti, LLC (KSF) has issued a notice to investors in Erasca, Inc. regarding a class action securities lawsuit. The lawsuit alleges that Erasca and its executives failed to disclose material information regarding the ERAS-0015 product, particularly concerning improper comparisons and potential patent violations. Investors who purchased Erasca shares between January 14, 2025, and April 26, 2026, have until August 10, 2026, to apply to be lead plaintiff.
ERASCA LEAD PLAINTIFF DEADLINE AUGUST 10th: Bragar Eagel & Squire, P.C. Reminds Erasca, Inc. (ERAS) Investors with Large Losses to Contact the Firm Regarding their Rights
Bragar Eagel & Squire, P.C. has filed a class action lawsuit against Erasca, Inc. (ERAS) on behalf of investors who purchased stock between January 14, 2025, and April 26, 2026. The lawsuit alleges that Erasca made misleading statements regarding its drug ERAS-0015, which was later accused of infringing on a Revolution Medicines patent and misappropriating trade secrets, leading to a significant drop in Erasca's stock price. Investors have until August 10, 2026, to apply to be lead plaintiff.
Kaplan Fox Urges Erasca, Inc. (NASDAQ: ERAS) Investors to Contact the Firm Before the Deadline on August 10, 2026
Kaplan Fox & Kilsheimer LLP has filed a class action lawsuit against Erasca, Inc. (NASDAQ: ERAS) on behalf of investors who purchased securities between January 14, 2025, and April 26, 2026. The lawsuit alleges that Erasca made misleading statements regarding its ERAS-0015 drug, particularly concerning its preclinical data and alleged infringement of a Revolution Medicines, Inc. patent. Investors who suffered losses are encouraged to contact Kaplan Fox before the lead plaintiff deadline of August 10, 2026.
Erasca, Inc. Notice of August 10, 2026 Application Deadline for Class Action Lawsuit - Contact Lewis Kahn, Esq. at Kahn Swick & Foti, LLC, Before Application Deadline
Kahn Swick & Foti, LLC (KSF) has notified investors of Erasca, Inc. (NASDAQ: ERAS) about a class action securities lawsuit. The lawsuit alleges that Erasca and its executives failed to disclose material information regarding the ERAS-0015 product's preclinical data, which was based on improper comparisons and risked violating patent protections. Investors who suffered losses during the Class Period (January 14, 2025, to April 26, 2026) have until August 10, 2026, to apply for lead plaintiff status.
ERAS UPCOMING DEADLINE : The Gross Law Firm Alerts Erasca,
The Gross Law Firm has issued a notice to shareholders of Erasca, Inc. (NASDAQ: ERAS) regarding a securities class action lawsuit. The complaint alleges that Erasca made materially false and/or misleading statements concerning ERAS-0015's preclinical data and its potential violation of patent and trade secret protections. Shareholders who purchased ERAS shares between January 14, 2025, and April 26, 2026, are encouraged to contact the firm, with a lead plaintiff deadline set for August 10, 2026.
Erasca Shareholder Alert: ClaimsFiler Reminds Investors
ClaimsFiler is reminding investors in Erasca, Inc. (NasdaqGS: ERAS) that they have until August 10, 2026, to apply for lead plaintiff in a securities class action lawsuit. The lawsuit alleges that Erasca and its executives failed to disclose material information regarding the preclinical data for its ERAS-0015 product, violating federal securities laws. Investors who purchased Erasca securities between January 14, 2025, and April 26, 2026, are affected.
ERAS STOCKHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Erasca, Inc. Investors with Losses Have Opportunity to Lead Class Action Lawsuit!
Bronstein, Gewirtz & Grossman, LLC has filed a class action lawsuit against Erasca, Inc. (NASDAQ:ERAS) on behalf of investors who purchased securities between January 14, 2025, and April 26, 2026. The lawsuit alleges that Erasca made misleading statements regarding ERAS-0015's preclinical data, which was based on improper comparisons and risked violating patent protections. Investors who suffered losses have until August 10, 2026, to apply to be lead plaintiff in the case.
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Erasca, Inc. of Class Action Lawsuit and Upcoming Deadlines - ERAS
Pomerantz LLP has announced a class action lawsuit against Erasca, Inc. (NASDAQ: ERAS) for alleged securities fraud, urging investors with losses to come forward by the August 10, 2026, deadline. The lawsuit stems from two significant stock drops in April 2026. The first followed Erasca's disclosure of a patent infringement and trade secret misappropriation claim by Revolution Medicines, and the second occurred after the company reported preliminary Phase 1 clinical data for ERAS-0015, which included the death of a patient and clarifications on comparative data limitations.
Kaplan Fox Urges Erasca, Inc. (NASDAQ: ERAS) Investors to Contact the Firm Before the Deadline on August 10, 2026
Kaplan Fox & Kilsheimer LLP is urging investors of Erasca, Inc. (NASDAQ: ERAS) to contact the firm by the August 10, 2026 deadline to serve as lead plaintiff in a class action lawsuit. The lawsuit alleges that Erasca made false and misleading statements regarding its drug ERAS-0015, which is accused of infringing a Revolution Medicines patent and involving trade secret misappropriation. Following the disclosure of these allegations, Erasca's stock price fell by nearly 11%.
Erasca, Inc. Deadline: ERAS Investors with Losses in Excess of $100K Have Opportunity to Lead Erasca, Inc. Securities Fraud Lawsuit
The Rosen Law Firm is reminding investors of Erasca, Inc. (NASDAQ: ERAS) who suffered losses exceeding $100,000 during the period of January 14, 2025, to April 26, 2026, about the August 10, 2026 deadline to apply to be lead plaintiff in a securities fraud lawsuit. The lawsuit alleges that Erasca, its CEO, and CFO made false and misleading statements regarding their lead oncology drug candidate, ERAS-0015, specifically concerning its purported "best-in-class" potential and misleading comparisons to a competing drug. Investors can join the class action by contacting the Rosen Law Firm.
ERAS INVESTOR ALERT: Erasca, Inc. Investors with Substantial Losses Have Opportunity to Lead Shareholder Class Action Lawsuit
Hagens Berman is investigating potential securities law violations by Erasca, Inc. (NASDAQ: ERAS) following allegations that the company misled investors about its lead oncology candidate, ERAS-0015. The lawsuit claims Erasca provided a false narrative concerning the drug's competitive advantage, safety, and intellectual property, leading to significant investor losses. Investors who suffered losses between January 14, 2025, and April 26, 2026, have until August 10, 2026, to move for lead plaintiff status.
ERAS Investors Have Opportunity to Lead Erasca, Inc. Securities Fraud Lawsuit with SBS Law
Schall, Brown & Schwartz LLP is reminding investors of a class action lawsuit against Erasca, Inc. (NASDAQ: ERAS) for alleged violations of the Securities Exchange Act. The lawsuit claims Erasca made false and misleading statements regarding preclinical data for ERAS-0015, which was improperly compared and risked patent infringement. Shareholders who purchased ERAS shares between January 14, 2025, and April 26, 2026, are encouraged to contact the firm by the August 10, 2026, deadline to discuss leading the lawsuit.
Erasca, Inc. Deadline: ERAS Investors with Losses in Excess of $100K Have Opportunity to Lead Erasca, Inc. Securities Fraud Lawsuit
Rosen Law Firm is reminding investors of Erasca, Inc. (NASDAQ: ERAS) who purchased common stock between January 14, 2025, and April 26, 2026, about the August 10, 2026 deadline to serve as lead plaintiff in a securities fraud lawsuit. The lawsuit alleges that Erasca made false and misleading statements about its oncology drug candidate, ERAS-0015, specifically regarding improper comparisons to a competitor's drug and a lack of reasonable basis for its claims. Investors with losses exceeding $100,000 have the opportunity to lead this class action and seek compensation.
ERAS 3-DAY DEADLINE ALERT: Erasca, Inc. Investors with
Hagens Berman is investigating Erasca, Inc. (NASDAQ: ERAS) for alleged securities law violations, claiming the company misled investors about its lead oncology candidate, ERAS-0015. The lawsuit alleges Erasca misrepresented the drug's competitive advantage, safety, and intellectual property, leading to a significant stock decline after disclosures of patent infringement and a patient death. Investors who suffered substantial losses between January 14, 2025, and April 26, 2026, have until August 10, 2026, to move for lead plaintiff appointment.
Erasca, Inc. Notice of August 10, 2026 Application Deadline
Hagens Berman, a national shareholder rights firm, is investigating a class action lawsuit against Erasca, Inc. (NASDAQ: ERAS) for alleged securities law violations. The lawsuit claims that Erasca and its executives misled investors about its lead oncology candidate, ERAS-0015, by providing a false narrative regarding its competitive advantage, safety profile, and intellectual property. Investors who suffered significant losses between January 14, 2025, and April 26, 2026, are urged to contact Hagens Berman before the August 10, 2026, lead plaintiff deadline.
Erasca earnings on deck: Can pipeline progress offset losses?
Erasca Inc. is set to report second-quarter results, with investor focus primarily on updates regarding its pan-RAS cancer drug, ERAS-0015, rather than expected financial losses. Despite being pre-revenue, analysts have a "Buy" rating on the stock with a significant price target, driven by promising early clinical data and the company's recent $550 million capital raise. Key investor concerns will include clinical trial progress, cash burn rate, and competitive positioning in the pan-RAS oncology space.
Bronstein, Gewirtz & Grossman LLC Urges Erasca, Inc. Investors to Act: Class Action Filed Alleging Investor Harm
Bronstein, Gewirtz & Grossman LLC has filed a class action lawsuit against Erasca, Inc. (NASDAQ: ERAS) on behalf of investors who purchased securities between January 14, 2025,
Erasca, Inc. (ERAS) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit
The Law Offices of Frank R. Cruz announced an opportunity for Erasca, Inc. (ERAS) shareholders who suffered losses to lead a securities fraud class action lawsuit. The lawsuit alleges that between January 14, 2025, and April 26, 2026, Erasca made materially false and misleading statements and failed to disclose adverse facts, specifically regarding its ERAS-0015 preclinical data and potential patent violations. Investors have until August 10, 2026, to participate as lead plaintiffs in the lawsuit.
Erasca, Inc. (ERAS) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit
The Law Offices of Frank R. Cruz have announced a securities fraud class action lawsuit against Erasca, Inc. (ERAS). Investors who suffered losses between January 14, 2025, and April 26, 2026, are encouraged to come forward before the August 10, 2026, lead plaintiff deadline. The lawsuit alleges that Erasca made misleading statements by basing ERAS-0015's preclinical data on improper comparisons, potentially violating patent and trade secret protections.
ERAS INVESTOR ALERT: Erasca, Inc. Investors with Substantial Losses Have Opportunity to Lead Shareholder Class Action Lawsuit
Hagens Berman is investigating a class action lawsuit against Erasca, Inc. (NASDAQ: ERAS) for alleged securities law violations. The lawsuit claims Erasca misled investors about its lead oncology candidate, ERAS-0015, by making flawed comparisons, concealing IP disputes, and downplaying safety risks, which led to a significant stock decline. Investors who suffered substantial losses between January 14, 2025, and April 26, 2026, have an opportunity to lead the class action by the August 10, 2026 deadline.
Bronstein, Gewirtz & Grossman LLC Urges Erasca, Inc. Investors to Act: Class Action Filed Alleging Investor Harm
Bronstein, Gewirtz & Grossman LLC has announced a class action lawsuit against Erasca, Inc. and its officers, alleging violations of federal securities laws. The lawsuit claims that Erasca made false and misleading statements regarding its drug ERAS-0015, specifically concerning its preclinical data and potential patent infringement. Investors who purchased Erasca securities between January 14, 2025, and April 26, 2026, are encouraged to join the case, with a lead plaintiff deadline of August 10, 2026.
